 Lisa Brents
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Naphthalenes | 9 | 2015 | 56 | 1.580 |
Why?
| | Neonatal Abstinence Syndrome | 2 | 2023 | 27 | 1.390 |
Why?
| | Receptor, Cannabinoid, CB1 | 9 | 2015 | 39 | 1.290 |
Why?
| | Indoles | 10 | 2015 | 504 | 1.280 |
Why?
| | Buprenorphine | 2 | 2023 | 190 | 1.040 |
Why?
| | Personality Disorders | 2 | 2018 | 78 | 0.940 |
Why?
| | Aromatase | 1 | 2023 | 32 | 0.800 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 601 | 0.750 |
Why?
| | Mitragyna | 1 | 2022 | 8 | 0.730 |
Why?
| | Cannabinoids | 3 | 2013 | 182 | 0.710 |
Why?
| | Behavioral Research | 1 | 2021 | 35 | 0.660 |
Why?
| | Morphine | 2 | 2024 | 169 | 0.650 |
Why?
| | Narcotics | 1 | 2021 | 58 | 0.650 |
Why?
| | Substance-Related Disorders | 2 | 2022 | 1090 | 0.580 |
Why?
| | Neuroticism | 1 | 2018 | 14 | 0.560 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 1142 | 0.550 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2018 | 31 | 0.540 |
Why?
| | Cocaine-Related Disorders | 2 | 2018 | 133 | 0.520 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 641 | 0.500 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2019 | 187 | 0.490 |
Why?
| | Personality | 1 | 2018 | 128 | 0.490 |
Why?
| | Endocannabinoids | 1 | 2016 | 57 | 0.460 |
Why?
| | Receptors, Cannabinoid | 2 | 2012 | 14 | 0.440 |
Why?
| | Fetus | 1 | 2019 | 800 | 0.420 |
Why?
| | Glucuronosyltransferase | 2 | 2012 | 18 | 0.370 |
Why?
| | Rats, Long-Evans | 2 | 2023 | 127 | 0.350 |
Why?
| | Hemiterpenes | 1 | 2011 | 11 | 0.350 |
Why?
| | Rats | 5 | 2024 | 5570 | 0.350 |
Why?
| | Plant Extracts | 1 | 2013 | 188 | 0.350 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2011 | 6 | 0.350 |
Why?
| | Stilbenes | 1 | 2011 | 33 | 0.350 |
Why?
| | Pregnancy | 5 | 2024 | 7122 | 0.310 |
Why?
| | Receptors, Opioid, mu | 3 | 2023 | 66 | 0.300 |
Why?
| | Binding, Competitive | 4 | 2013 | 182 | 0.290 |
Why?
| | Child Abuse | 1 | 2015 | 549 | 0.290 |
Why?
| | Body Temperature | 4 | 2015 | 226 | 0.280 |
Why?
| | Behavior, Animal | 1 | 2012 | 521 | 0.280 |
Why?
| | Pain | 1 | 2013 | 785 | 0.260 |
Why?
| | Dronabinol | 4 | 2015 | 249 | 0.260 |
Why?
| | Animals, Newborn | 2 | 2021 | 890 | 0.260 |
Why?
| | Animals | 16 | 2024 | 37948 | 0.250 |
Why?
| | Stress, Psychological | 1 | 2015 | 1148 | 0.240 |
Why?
| | Hydroxylation | 4 | 2012 | 49 | 0.220 |
Why?
| | Receptor, Cannabinoid, CB2 | 3 | 2013 | 11 | 0.220 |
Why?
| | Hypothermia | 2 | 2015 | 52 | 0.200 |
Why?
| | Female | 10 | 2024 | 78304 | 0.170 |
Why?
| | Infant, Newborn | 2 | 2023 | 6399 | 0.170 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 205 | 0.170 |
Why?
| | Automation | 1 | 2021 | 104 | 0.160 |
Why?
| | Cricetinae | 4 | 2013 | 296 | 0.150 |
Why?
| | Video Recording | 1 | 2021 | 217 | 0.150 |
Why?
| | Ethanol | 1 | 2024 | 627 | 0.150 |
Why?
| | Molecular Structure | 4 | 2013 | 495 | 0.140 |
Why?
| | ROC Curve | 1 | 2021 | 618 | 0.140 |
Why?
| | Motor Activity | 2 | 2015 | 723 | 0.140 |
Why?
| | Movement | 1 | 2021 | 295 | 0.140 |
Why?
| | Pain Management | 1 | 2022 | 410 | 0.140 |
Why?
| | Humans | 17 | 2023 | 144671 | 0.130 |
Why?
| | CHO Cells | 3 | 2013 | 165 | 0.130 |
Why?
| | Placenta | 1 | 2023 | 781 | 0.130 |
Why?
| | Alcohol Drinking | 1 | 2024 | 827 | 0.120 |
Why?
| | Risk | 1 | 2019 | 911 | 0.120 |
Why?
| | Pentacyclic Triterpenes | 2 | 2012 | 12 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1995 | 0.120 |
Why?
| | Ligands | 3 | 2013 | 662 | 0.120 |
Why?
| | Mice | 8 | 2015 | 18261 | 0.120 |
Why?
| | Brain | 4 | 2024 | 2934 | 0.120 |
Why?
| | Software | 1 | 2021 | 695 | 0.110 |
Why?
| | Menstrual Cycle | 1 | 2016 | 140 | 0.110 |
Why?
| | Drug Tolerance | 1 | 2015 | 99 | 0.110 |
Why?
| | Personality Assessment | 1 | 2015 | 79 | 0.110 |
Why?
| | Fertility | 1 | 2016 | 166 | 0.110 |
Why?
| | Progesterone | 1 | 2016 | 209 | 0.110 |
Why?
| | Male | 8 | 2024 | 72431 | 0.110 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2012 | 161 | 0.110 |
Why?
| | Mice, Inbred Strains | 2 | 2012 | 396 | 0.110 |
Why?
| | Kinetics | 3 | 2012 | 1603 | 0.100 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 524 | 0.100 |
Why?
| | Cyclohexanols | 1 | 2013 | 10 | 0.100 |
Why?
| | Adenylyl Cyclase Inhibitors | 1 | 2013 | 7 | 0.100 |
Why?
| | Membranes | 1 | 2013 | 13 | 0.100 |
Why?
| | Quinuclidines | 1 | 2013 | 11 | 0.100 |
Why?
| | Conditioning, Operant | 1 | 2013 | 98 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2015 | 539 | 0.090 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2521 | 0.090 |
Why?
| | Drug Synergism | 1 | 2013 | 352 | 0.090 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2012 | 45 | 0.090 |
Why?
| | Anticarcinogenic Agents | 1 | 2012 | 61 | 0.090 |
Why?
| | YY1 Transcription Factor | 1 | 2012 | 24 | 0.090 |
Why?
| | Drug Partial Agonism | 1 | 2012 | 2 | 0.090 |
Why?
| | Drug Antagonism | 1 | 2012 | 9 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2015 | 1301 | 0.090 |
Why?
| | Triterpenes | 1 | 2012 | 25 | 0.090 |
Why?
| | Metabolic Detoxication, Phase II | 1 | 2011 | 3 | 0.090 |
Why?
| | Prenylation | 1 | 2011 | 3 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 401 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 36 | 0.090 |
Why?
| | Protein Binding | 3 | 2013 | 2243 | 0.090 |
Why?
| | Mass Spectrometry | 2 | 2012 | 743 | 0.090 |
Why?
| | Isoproterenol | 1 | 2012 | 96 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2012 | 1363 | 0.090 |
Why?
| | Adrenergic beta-Agonists | 1 | 2012 | 92 | 0.090 |
Why?
| | In Vitro Techniques | 1 | 2013 | 1046 | 0.090 |
Why?
| | Biological Availability | 1 | 2011 | 143 | 0.080 |
Why?
| | GTP-Binding Proteins | 1 | 2012 | 153 | 0.080 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2012 | 176 | 0.080 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2012 | 125 | 0.080 |
Why?
| | Pain Measurement | 1 | 2013 | 554 | 0.080 |
Why?
| | Piperidines | 1 | 2012 | 219 | 0.080 |
Why?
| | Psychomotor Performance | 1 | 2013 | 328 | 0.080 |
Why?
| | Protein Transport | 1 | 2012 | 437 | 0.080 |
Why?
| | Narcotic Antagonists | 1 | 2012 | 204 | 0.080 |
Why?
| | Young Adult | 2 | 2018 | 14122 | 0.080 |
Why?
| | Down-Regulation | 1 | 2012 | 616 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 580 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2117 | 0.070 |
Why?
| | Cannabis | 1 | 2016 | 509 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 613 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 2019 | 0.070 |
Why?
| | Repressor Proteins | 1 | 2012 | 428 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 512 | 0.070 |
Why?
| | Cell Membrane | 1 | 2012 | 706 | 0.070 |
Why?
| | Models, Molecular | 1 | 2011 | 1610 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 689 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2013 | 4110 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6041 | 0.060 |
Why?
| | United States | 1 | 2022 | 16018 | 0.050 |
Why?
| | Middle Aged | 2 | 2018 | 35971 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2024 | 45 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10796 | 0.050 |
Why?
| | Adult | 2 | 2018 | 40489 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2001 | 22 | 0.040 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2001 | 46 | 0.040 |
Why?
| | Cyclins | 1 | 2001 | 79 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2001 | 118 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2001 | 160 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2365 | 0.040 |
Why?
| | Multiple Myeloma | 1 | 2001 | 306 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2873 | 0.030 |
Why?
| | Adolescent | 1 | 2015 | 22409 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2014 | 115 | 0.030 |
Why?
| | Stereoisomerism | 1 | 2013 | 102 | 0.020 |
Why?
| | Cytochrome P-450 CYP1A2 | 1 | 2012 | 4 | 0.020 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2012 | 19 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 7 | 0.020 |
Why?
| | Drug Inverse Agonism | 1 | 2012 | 3 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2014 | 570 | 0.020 |
Why?
| | Psychotropic Drugs | 1 | 2013 | 77 | 0.020 |
Why?
| | Sp Transcription Factors | 1 | 2012 | 3 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 2012 | 85 | 0.020 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 45 | 0.020 |
Why?
| | Cricetulus | 1 | 2012 | 114 | 0.020 |
Why?
| | Glucuronides | 1 | 2012 | 18 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 12 | 0.020 |
Why?
| | Morpholines | 1 | 2012 | 129 | 0.020 |
Why?
| | rab GTP-Binding Proteins | 1 | 2012 | 76 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2012 | 205 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 677 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 396 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 743 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2591 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 1078 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1437 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2489 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3523 | 0.010 |
Why?
| | Liver | 1 | 2012 | 1889 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2397 | 0.010 |
Why?
| | Neurons | 1 | 2012 | 1639 | 0.010 |
Why?
| | Cyclin D3 | 1 | 2001 | 4 | 0.010 |
Why?
| | Cytogenetic Analysis | 1 | 2001 | 33 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2001 | 321 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2001 | 881 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2001 | 441 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2001 | 3603 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2001 | 2815 | 0.010 |
Why?
|
|
Brents's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|